Safety and efficacy of drug-eluting stents compared with bare metal stents in ST-elevation myocardial infarction

Reviews in Cardiovascular Medicine

Volumn 11, Issue 2, 2010, Pages 57-73

  Beattie, Meaghan J ^a   Lee, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bare metal stent; Drug eluting stent; Percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

ABCIXIMAB; BIOLIMUS; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TACROLIMUS; TIROFIBAN; UNCLASSIFIED DRUG; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT; METAL;

BARE METAL STENT; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE REGISTRY; DRUG ELUTING STENT; DRUG MEGADOSE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MEDICAL LITERATURE; PATIENT SAFETY; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; EVIDENCE BASED MEDICINE; HEART INFARCTION; INSTRUMENTATION; PATIENT SELECTION; PROSTHESIS; RISK ASSESSMENT; RISK FACTOR; STENT; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957352796     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0517     Document Type: Review

References (88)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
2. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88:297-301.
3. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008;126:37-44.
4. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007;50:463-470.
5. Moreno R, Fernández C, Hernández R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959.
6. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030-1039.
7. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989-997.
8. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008;118:1817-1827.
9. Roukoz H, Bavry AA, Sarkees ML, et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009;122:581.e1-e10.
10. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
11. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-1947.
12. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-2009.
13. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-1058.
14. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138-1145.
15. Daemen J, Tanimoto S, García-García HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007;99:1027-1032.
16. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133:213-222.
17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.
18. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 1989;320:618-627.
19. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
20. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-356.
21. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-2434.
22. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172-209.
23. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al; the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol. 2006;48:2584-2591.
24. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
25. Valgimigli M, Percoco G, Malagutti P, et al; the STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293:2109-2117.
26. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105-1113.
27. Díaz de la Llera LS, Ballesteros S, Nevado J, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J. 2007;154:164.e1-e6.
28. Tierala I, Syvanne M, Kupari M; for the HAAMU study group. Comparison of paclitaxel-eluting with bare-metal stents in acute myocardial infarction. The HAAMU-STENT-study. TCTMD Web site. http://www.tctmd.com/show.aspx? id-56036. Accessed June 20, 2009.
29. van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol. 2008;51:618-626.
30. Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol. 2007;49:1924-1930.
31. Siqueira DA, Abizaid AA, Costa Jde R, et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J. 2007;28:1304-1309.
32. Kelbaek H, Thuesen L, Helqvist S, et al. Drug-eluting versus bare metal stents in patients with ST-segment elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation. 2008;118:1155-1162.
33. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093-1104.
34. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA. 2008;299:1788-1799.
35. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-1959.
36. Chechi T, Vittori G, Biondi Zoccai GL, et al. Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION). J Interv Cardiol. 2007;20:282-291.
37. Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) randomized trial. JACC Cardiovasc Interv. 2009;2:515-523.
38. Pittl U, Kaiser C, Brunner-La Rocca HP, et al. Safety and efficacy of drug eluting stents versus bare metal stents in primary angioplasty of patients with acute ST-elevation myocardial infarction - a prospective randomized study [abstract]. Eur Heart J. 2006;27:650.
39. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation or thienopyridine therapy after drug-eluting stent placement. Circulation. 2006;113:2803-2809.
40. De Luca G, Cassetti E, Marino P. Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials. J Thromb Thrombolysis. 2009;27:365-378.
41. Pasceri V, Patti G, Speciale G, et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J. 2007;153:749-754.
42. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706-2713.
43. Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53:1677-1689.
44. De Luca G, Valgimigli M, Spaulding C, et al.Short- and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis. 2009;28:200-210.
45. Cheneau E, Rha SW, Kuchulakanti PK, et al. Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Catheter Cardiovasc Interv. 2005;65:469-472.
46. Kupferwasser LI, Amorn AM, Kapoor N, et al. Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction. Catheter Cardiovasc Interv. 2007;70:1-8.
47. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:704-708.
48. Slottow TL, Steinberg DH, Roy P, et al. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med. 2008;9:24-28.
49. Kornowski R, Vaknin-Assa H, Lev E, et al. Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction. Acute Card Care. 2008;10:167-172.
50. Zahn R, Hamm CW, Schneider S, et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the Prospective Multicenter German Cypher Stent Registry). Am J Cardiol. 2005;95:1302-1308.
51. Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428-1436.
52. Percoco G, Manari A, Guastaroba P, et al. Safety and long-term efficacy of sirolimus eluting stent in st-elevation acute myocardial infarction: the REAL (Registro Regionale AngiopLastiche Emilia-Romagna) registry. Cardiovasc Drugs Ther. 2006;20:63-68.
53. Steg PG, Fox KA, Eagle KA, et al; the Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J. 2009;30:321-329.
54. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007;116:2391-2398.
55. Lemesle G, Pinto Slottow TL, Waksman R. Very late stent thrombosis after bare-metal stent implantation: case reports and review of the literature. J Invasive Cardiol. 2009;21:E27-E32.
56. Hannan EL, Racz M, Walford G, et al. Drug-eluting versus bare-metal stents in the treatment of patients with st-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1:129-135.
57. Shishehbor MH, Amini R, Oliveria LP, et al. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1:227-234.
58. Bose R, Gupta G, Grayburn PA, et al. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center. Am J Cardiol. 2007;100:949-952.
59. Jensen LO, Maeng M, Thayssen P, et al. Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with st-segment elevation myocardial infarction. Circ Cardiovasc Interv. 2008;1:176-184.
60. Romano M, Buffoli F, Tomasi L, et al. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty. Catheter Cardiovasc Interv. 2008;71:759-763.
61. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330-1342.
62. Vagaonescu TD, Moreyra AE, Wilson AC, et al. Long-term mortality in ST-T segment and non-ST-T segment myocardial infarction after drug-eluting stents and bare metal stents implantation in New Jersey: the MIDAS Registry. Paper presented at: 19th Annual Symposium of Transcatheter and Cardiovascular Therapeutics; October 20-25, 2007; Washington, DC.
63. Brodie BR, Stuckey T, Downey W, et al. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheter Cardiovasc Interv. 2008;72:893-900.
64. Vlaar PJ, Rihal CS, Singh M, et al. Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort. Catheter Cardiovasc Interv. 2008;71:764-769.
65. Kukreja N, Onuma Y, García-García H, et al. Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. Circ Cardiovasc Interv. 2008;1:103-110.
66. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation. 2003;107:2274-2279.
67. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869-1876.
68. Kittleson MM, Needham DM, Kim SJ, et al. The efficacy of sirolimus- and paclitaxel-eluting stents: a meta-analysis of randomized controlled trials. Can J Cardiol. 2005;21:581-587.
69. Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry - STENT Group. J Am Coll Cardiol. 2007;50:1214-1222.
70. Waksman R, Buch AN, Torguson R, et al. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS Registry). Am J Cardiol. 2007;100:45-51.
71. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-1061.
72. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295:895-904.
73. Galløe AM, Thuesen L, Kelbaek H, et al; SORT OUT II Investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008;299:409-416.
74. Berger A, Stauffer JC, Seydoux C, et al. Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. Catheter Cardiovasc Interv. 2007;70:163-166.
75. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662.
76. Schömig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373-1380.
77. Park KW, Cho YS, Chung JW, et al. One year clinical and six month angiographic results of drug eluting stents for ST elevation acute myocardial infarction: 'real world' comparison between sirolimus- and paclitaxel-eluting stents. Int J Cardiol. 2009;131:350-355.
78. Juwana YB, Suryapranata H, Ottervanger JP, et al. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol. 2009;104:205-209.
79. Lee JH, Kim HS, Lee SW, et al. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv. 2008;72:25-32.
80. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
81. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48:2440-2447.
82. Jain AK, Meredith IT, Lotan C, et al. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry. Am J Cardiol. 2007;100(suppl):77M-83M.
83. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomized non-inferiority trial. Lancet. 2008;372:1163-1173.
84. Daemen J, Serruys PW. Drug-eluting stent update 2007: part II: unsettled issues. Circulation. 2007;116:961-968.
85. Tamburino C, Di Salvo ME, Capodanno D, et al. Real world safety and efficacy of the Janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. Catheter Cardiovasc Interv. 2009;73:243-248.
86. Rinker A, Nusser T, Grossman G, et al. Angiographic results of a tacrolimus-eluting stent in acute coronary syndrome lesions. Clin Res Cardiol. 2009;98:89-93.
87. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) Registry. J Am Coll Cardiol. 2009;54:269-275.
88. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680-686.